Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.

Name: Αlpha¹ Rigor Record — Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
Item: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
Rating: 94
Author: Αlpha¹

EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Agrawal N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Zhu D, Dayanandan R, Arimoto R, Mayne KJ, Ng SYA, Sammons E, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney DZI, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Massey D, Brueckmann M, Landray MJ, Baigent C, Haynes R, EMPA-KIDNEY Collaborative Group

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 4.25★ (Strong), 0 critical, 2 high issues for “Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

4.25 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 4 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Problems surfaced2 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted randomized controlled trial with extended post-trial follow-up, reporting robust methodology, clear reporting of demographics, and appropriate statistical analyses. The main weakness is the vague data availability statement and lack of code sharing, which limits reproducibility.

Both reviewers classified the study as interventional, which is appropriate given the randomized controlled trial design with post-trial observational follow-up. The statistics verification covered only a subset of reported tests (11 recomputed consistently); the remaining statistics are unverified. The citation check found no retracted or unresolved references.

9 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 11 tests: 11 consistent, 0 inconsistent; 11 via agent-written checks.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites prior trials and the rationale for post-trial follow-up, acknowledging the active trial's limitations (short duration, low number of ESKD outcomes). The hypothesis that benefits may persist after discontinuation is logically derived from the premise.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior evidence on SGLT2 inhibitors and the rationale for post-trial follow-up.

Evidence

direct quote[Introduction, paragraph 1]

“Findings from the active part of this trial and other large trials provided compelling evidence that SGLT2 inhibitors substantially slowed kidney disease progression and reduced cardiovascular risk.”